Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL By Ogkologos - June 9, 2026 85 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the frontMIND study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... July 25, 2025 Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL September 21, 2021 For Some Women with Breast Cancer, Cost Influences Decisions about Surgery September 6, 2019 Load more HOT NEWS Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful... Coronavirus reports: “As a Black man with advanced prostate cancer, who... Experimental Cancer Drug Metarrestin Targets Metastatic Tumors Bride Learns Sign Language, Surprises Groom’s Deaf Parents & Signs Her...
